CN101018555A - 用羟基碳酸镧治疗高磷酸盐血症的方法 - Google Patents

用羟基碳酸镧治疗高磷酸盐血症的方法 Download PDF

Info

Publication number
CN101018555A
CN101018555A CNA2005800309851A CN200580030985A CN101018555A CN 101018555 A CN101018555 A CN 101018555A CN A2005800309851 A CNA2005800309851 A CN A2005800309851A CN 200580030985 A CN200580030985 A CN 200580030985A CN 101018555 A CN101018555 A CN 101018555A
Authority
CN
China
Prior art keywords
lanthanum
ckd
lanthanum hydroxycarbonate
individual
hydroxycarbonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800309851A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·费迪南多
D·吉尔摩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Pharmaceuticals Inc
Original Assignee
Shire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Inc filed Critical Shire Pharmaceuticals Inc
Publication of CN101018555A publication Critical patent/CN101018555A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2005800309851A 2004-07-27 2005-07-27 用羟基碳酸镧治疗高磷酸盐血症的方法 Pending CN101018555A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59110504P 2004-07-27 2004-07-27
US60/591,105 2004-07-27

Publications (1)

Publication Number Publication Date
CN101018555A true CN101018555A (zh) 2007-08-15

Family

ID=35787449

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800309851A Pending CN101018555A (zh) 2004-07-27 2005-07-27 用羟基碳酸镧治疗高磷酸盐血症的方法

Country Status (14)

Country Link
US (1) US20060153932A1 (https=)
EP (1) EP1708723A4 (https=)
JP (1) JP4869229B2 (https=)
KR (2) KR20070054191A (https=)
CN (1) CN101018555A (https=)
AU (1) AU2005269362B2 (https=)
BR (1) BRPI0513603A (https=)
CA (1) CA2574450C (https=)
EA (1) EA010980B1 (https=)
MX (1) MX2007001114A (https=)
NO (1) NO20070906L (https=)
NZ (1) NZ552861A (https=)
WO (1) WO2006015055A1 (https=)
ZA (1) ZA200701707B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
MXPA06002257A (es) * 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.
JP2008516971A (ja) * 2004-10-15 2008-05-22 アルテアーナノ，インコーポレーテッド 錠剤による負荷が軽減されるリン酸塩結合剤
US20080058250A1 (en) * 2005-08-17 2008-03-06 Allison Wren Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
EP3066923B1 (en) * 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Method of treating chronic kidney disease
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
EP1852695B1 (en) * 2006-05-05 2011-10-26 Shire International Licensing B.V. Assay for lanthanum hydroxy carbonate
US8961917B2 (en) * 2010-05-12 2015-02-24 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
GB201501000D0 (en) * 2015-01-21 2015-03-04 Univ Edinburgh Lanthanum thiosulfate and methods of preparation of the same
WO2017072256A1 (en) * 2015-10-27 2017-05-04 MEDICE Arzneimittel Pütter GmbH & Co. KG Nicotinamide for lowering phosphate levels in hyperphosphatemia
KR101880447B1 (ko) * 2015-12-01 2018-07-23 김배용 생리활성물질 복합체, 이의 제조방법 및 이를 포함한 화장료 조성물
KR101684289B1 (ko) 2016-05-17 2016-12-09 한국식품연구원 락토바실러스 sp. KCCM 11826P 균주를 이용한 고인산혈증 예방, 만성 신장질환 치료용 약학조성물 및 건강기능성 식품
US10322409B1 (en) * 2018-03-05 2019-06-18 King Fahd University Of Petroleum And Minerals Low temperature hydrothermal method for the preparation of LaCO3OH nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4592082A (en) * 1984-08-10 1986-05-27 The United States Of America As Represented By The United States Department Of Energy Quantitative determination of mineral composition by powder X-ray diffraction
CA2117351C (en) * 1992-01-13 1998-03-03 Julian Belknap Lo Preparation of tablets of increased strength
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
US5435986A (en) * 1994-08-30 1995-07-25 Industrial Technology Research Institute Method for preparing high purity aluminum hydroxide
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
AU782304B2 (en) * 1999-09-02 2005-07-14 Acologix, Inc. Methods and compositions for reducing serum phosphate levels
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
DK1389102T3 (da) * 2001-04-23 2011-06-06 Shire Int Licensing Bv Anvendelse af lanthancarbonat til forebyggelse af nyresten
US7469036B2 (en) * 2002-04-19 2008-12-23 Los Alamos National Security, Llc Analysis of macromolecules, ligands and macromolecule-ligand complexes
AU2003229437A1 (en) * 2002-05-08 2003-11-11 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
MXPA06002257A (es) * 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.

Also Published As

Publication number Publication date
ZA200701707B (en) 2008-10-29
MX2007001114A (es) 2007-07-11
AU2005269362A1 (en) 2006-02-09
CA2574450C (en) 2011-07-19
KR20070054191A (ko) 2007-05-28
NO20070906L (no) 2007-04-23
WO2006015055A1 (en) 2006-02-09
US20060153932A1 (en) 2006-07-13
EP1708723A1 (en) 2006-10-11
EA200700273A1 (ru) 2007-08-31
JP4869229B2 (ja) 2012-02-08
KR101072196B1 (ko) 2011-10-10
EA010980B1 (ru) 2008-12-30
KR20090023743A (ko) 2009-03-05
CA2574450A1 (en) 2006-02-09
JP2008508297A (ja) 2008-03-21
AU2005269362B2 (en) 2010-08-12
BRPI0513603A (pt) 2008-05-13
NZ552861A (en) 2010-11-26
EP1708723A4 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
CN101018555A (zh) 用羟基碳酸镧治疗高磷酸盐血症的方法
Emmett et al. Calcium acetate control of serum phosphorus in hemodialysis patients
JP2008508297A5 (https=)
JP2005531532A (ja) アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
EP1768748B2 (en) Compositions comprising strontium and vitamin d and uses thereof
AU2010261967B2 (en) New therapeutical uses of inecalcitol
CN101304753B (zh) 镧化合物的制药用途
US6887897B2 (en) Calcium glutarate supplement and phosphorus binder
WO2012106947A1 (zh) 含维生素d和二甲双胍的药物组合物
Isenberg Therapy of peptic ulcer
HK1102545B (en) Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds
Pavlovic et al. Control of Hyperparathyroidism with Once Weekly Oral Pulse Calcitriol Therapy in a CAPD Patient
Rizzato Calcium metabolism
KR20060011615A (ko) 생체이용율이 증진된 알렌드론산 제제
Goodman Renal osteodystrophy: present and future
Hsu Historical Perspective of Calcium Management in Patients with Chronic Renal Diseases
BR112020018319A2 (pt) Composição farmacêutica para anemia
JPH09118616A (ja) 消化器症状改善剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070815